News

Mar
13
2024

Shareholder interview with AcouSort’s CEO Torsten Freltoft and Commercial Director Agnes Michanek

Read more about AcouSort’s ongoing collaborations within cell therapy as well as other focus areas for 2024 in the...

Read More
Feb
28
2024

Interim Report Q4 2023

Regulatory

Today, AcouSort releases its interim report for Q4 2023. The report can be found in both Swedish and English...

Read More
Feb
15
2024

AcouSort presents at RedEye Regenerative medicine/ Cell Therapy event

AcouSort’s CEO Torsten Freltoft presents at RedEye Regenerative medicine/ Cell Therapy event in Stockholm February 14 2024. Follow the...

Read More
Mar
13
2024

Shareholder interview with AcouSort’s CEO Torsten Freltoft and Commercial Director Agnes Michanek

Read more about AcouSort’s ongoing collaborations within cell therapy as well as other focus areas for 2024 in the...

Read More
Feb
28
2024

Interim Report Q4 2023

Regulatory

Today, AcouSort releases its interim report for Q4 2023. The report can be found in both Swedish and English...

Read More
Jan
31
2024

Significant technical progress in the AcouSome project – two novel patent applications filed

In August 2022, the European Innovation Council (EIC) awarded the AcouSort project AcouSome SEK 26 million to develop groundbreaking...

Read More
Feb
15
2024

AcouSort presents at RedEye Regenerative medicine/ Cell Therapy event

AcouSort’s CEO Torsten Freltoft presents at RedEye Regenerative medicine/ Cell Therapy event in Stockholm February 14 2024. Follow the...

Read More
Oct
18
2023

AcouSort presents at BioStock Life Science Summit October 26

Read more: https://www.biostock.se/biostock-life-science-fall-summit-2023/.

Read More
Oct
10
2023

CEO Torsten Freltoft presents AcouSort’s opportunities in cell therapy and diagnostics at LSX Nordic Congress on October 10

AcouSort is an innovative medical technology company developing critical components for instrumentation used in the diagnostics, analytics, and cell...

Read More